ライフサイエンスコーパス: kidney transplant

1 in end-stage renal disease patients awaiting kidney transplant.

2 against autoantigens and alloantigens after kidney transplant.

3 ar injury is inevitable, such as following a kidney transplant.

4 center or at home), peritoneal dialysis, and kidney transplant.

5 d intravenous immunoglobulin after his third kidney transplant.

6 rwent heart transplant and 1 underwent heart-kidney transplant.

7 rwent liver transplant and 2 underwent liver-kidney transplant.

8 kidney disease who is being evaluated for a kidney transplant.

9 and 49 290 (3.3%) received a deceased donor kidney transplant.

10 and mortality remain high in recipients of a kidney transplant.

11 astating cause of early allograft loss after kidney transplant.

12 hopes and prognostic expectations related to kidney transplant.

13 differ based on whether they have received a kidney transplant.

14 utious approach is needed with mother-to-son kidney transplants.

15 in 24 patients who had received living-donor kidney transplants.

16 association in a cohort of 1001 consecutive kidney transplants.

17 Seventeen patients (9 females) received 22 kidney transplants.

18 utious approach is needed with mother-to-son kidney-transplants.

19 ividuals with CKD (not on dialysis or with a kidney transplant): (1) Renal Impairment in Secondary Ca

20 eys waited a median 9.6 months for a non-IRD kidney transplant (11.2 mo among those <6 y, 8.8 mo amon

21 t with the previous Fontan operation), for a kidney transplant 2.8 (sickle cell nephropathy as primar

22 hat sociocultural disparities exist in early kidney transplant access and occur despite the absence o

23 for calculation of CPRA to improve equity in kidney transplant allocation.

24 g kidney, and categorized as: deceased-donor kidney transplant alone (DD-KA, 68%), living-donor kidne

25 om 1988 to 2015 and compared to their paired kidney transplant alone (KTA) recipients.

26 transplant alone (DD-KA, 68%), living-donor kidney transplant alone (LD-KA, 30%), or SPK (2%).

27 Five CIKTx or kidney transplant alone recipients were treated with aCD

28 ve a survival benefit compared to those with kidney transplant alone, but this benefit depends upon s

29 The 2 kidney transplant-alone recipients were treated with the

30 In children who have received a kidney transplant and fulfil the above growth criteria,

31 nal allograft failure (10 underwent a repeat kidney transplant); and 6 required amputation of part of

32 follow-up of 4.4 years, 179 (23%) received a kidney transplant, and 195 (25%) died.

33 list, 23 762 (1.6%) received a living donor kidney transplant, and 49 290 (3.3%) received a deceased

34 transplant, the second had a deceased donor kidney transplant, and the third had a pancreas after ki

35 A total of 1001 patients underwent kidney transplant, and were dismissed from the hospital

36 higher yearly volume (per 10 deceased donor kidney transplants; aOR, 1.08, 95% CI, 1.06-1.10), small

37 donation after cardiac death (DCD) liver and kidney transplants are improving.

38 nts with ESKD, 27,633 (5%) had a functioning kidney transplant at the time of death, 14,653 (3%) had

39 tlisted patients who subsequently received a kidney transplant at University Hospital Zurich, Switzer

40 Medicare-insured patients undergoing kidney transplant became increasingly medically complex

41 patients >=65 years of age receiving a first kidney transplant between 2010 and 2017.

42 Of 7668 deceased donor kidney transplants between 1997 and 2014, 1497 (19.5%) r

43 ell RNA sequencing (scRNA-seq) of five human kidney transplant biopsy cores distinguished immune cell

44 Exchange (GKE) programme seeks to facilitate kidney transplants by matching donor-recipient pairs acr

45 A kidney transplant candidate's social network serves as a

46 roving knowledge among African American (AA) kidney transplant candidates compared to other races.

47 June 28, 2018, and October 29, 2018, with 40 kidney transplant candidates to assess the feasibility a

48 at included all United States incident adult kidney transplant candidates wait listed in 2011 and 201

49 o accomplish this, two serum samples from 20 kidney transplant candidates with cPRA >=99.9% (100%) we

50 cate dramatic changes in prognoses for adult kidney transplant candidates, likely impacted by selecti

51 to impact IRD knowledge among AA and non-AA kidney transplant candidates.

52 n making for organ utilization for potential kidney transplant candidates.

53 ganciclovir for CMV prophylaxis in liver and kidney transplanted children as it showed satisfactory l

54 tic islets (PHPI) in patients with T1D after kidney transplant (CIT06), a National Institutes of Heal

55 1.6%, respectively, among 3293 patients with kidney transplants (compared with 0.6% in the general po

56 11-2015 data from a prospectively-maintained kidney transplant database from a single center.

57 tlisted and pursue deceased and living donor kidney transplant (DDKT and LDKT, respectively).

58 concerns regarding decreased deceased donor kidney transplant (DDKT) rates for pediatric candidates

59 failure or patient death) for deceased-donor kidney transplant (DDKT) recipients (n = 1288) and livin

60 -center data on 109 cPRA 100% deceased donor kidney transplant (DDKT) recipients to study post-KAS po

61 43.0% of decliners received a deceased donor kidney transplant (DDKT), 6.3% received living donor kid

62 ollow-up time of 4.70 years after the second kidney transplant, death-censored graft survival at 5 ye

63 Patients with kidney transplants display a high risk of mortality.

64 s, and psychosocial issues among transgender kidney transplant donors and recipients.

65 entified frequent transmission of JCPyV from kidney transplant donors to recipients.

66 ry of Transplant Recipients database for all kidney transplants during a 15-year period (July 1, 2001

67 vention) of the randomized Teen Adherence in Kidney transplant Effectiveness of Intervention trial.

68 Among 1216 patients with kidney transplants enrolled, 66 (5%) patients were ident

69 recipients sensitized to their living-donor kidney transplants (EudraCT 2010-019630-28).

70 enal disease (ESRD) patients from initiating kidney transplant evaluation is unknown.

71 Patients with ESKD who would benefit from a kidney transplant face a critical and continuing shortag

72 We performed a retrospective study of 332 kidney transplants facilitated by the Mayo 3-site KPD pr

73 ologic, and molecular variables with risk of kidney transplant failure after an indication biopsy, bo

74 Identifying biomarkers to predict kidney transplant failure and to define new therapeutic

75 bsets in blood improved prediction of 8-year kidney transplant failure compared with a clinical-varia

76 d composite of eight clinical variables, the Kidney Transplant Failure Score.

77 (+) T cell monitoring for predicting risk of kidney transplant failure.

78 c AMR identifies patients at higher risk for kidney transplant failure.

79 hout evidence of CSCC relapse and received a kidney transplant from a living-unrelated donor.

80 plant outcomes in individuals who received a kidney transplant from a standard criteria deceased dono

81 The patient received a living-related kidney transplant from his sister.

82 % specificity in distinguishing non-rejected kidney transplants from rejected ones.

83 We identified all kidney transplants from uncontrolled DCD between 2007 an

84 nt roles in the time to allograft failure in kidneys transplanted from deceased donors and the safety

85 Kidneys transplanted from deceased donors with serum cre

86 e effect of COIIN on kidney yield (number of kidneys transplanted from donors from whom any organ was

87 nephron size, and nephron number vary among kidneys transplanted from living donors.

88 Reducing length of stay after kidney transplant has an unknown effect on post-transpla

89 n in dialysis centers can increase access to kidney transplant; however, dialysis center transplant b

90 y, we prospectively identified referrals for kidney transplant in adult patients between June 2010 an

91 failure in patients (n = 181) who received a kidney transplant in Olmsted County, MN (January 1, 1998

92 an increasing proportion of all living donor kidney transplants in the United States.

93 e discarded United States kidneys to similar kidneys transplanted in Europe and calculated predicted

94 n) were significantly lower for female donor kidneys transplanted into both male (adjusted odds ratio

95 Kidney transplant is a life-changing procedure, and tran

96 Simultaneous liver-kidney transplant is a viable option to be considered in

97 sing patients from the hospital 2 days after kidney transplant is safe, feasible, and improves value.

98 reliably and validly measure ESRD patients' kidney transplant knowledge, rigorously tested measures

99 Clinical decision-making in kidney transplant (KT) during the coronavirus disease 20

100 Kidney transplant (KT) outcomes for HIV-infected (HIV+)

101 19 (COVID-19) pandemic has posed at risk the kidney transplant (KT) population.

102 Hepatitis C virus-positive (HCV+) kidney transplant (KT) recipients are at increased risks

103 sage is critical, particularly for high-risk kidney transplant (KT) recipients without cytomegaloviru

104 W) is associated with acceptable outcomes in kidney transplant (KT) recipients.

105 er length of stay and increased mortality in kidney transplant (KT) recipients.

106 Proper care of young children in need of kidney transplant (KT) requires many skilled professiona

107 eat nkSOT recipients who develop ESRD with a kidney transplant (KT), an increasing number are develop

108 Sixty-four patients underwent kidney transplant (KT), and 58 KT recipients had either

109 are needed to monitor stable patients after kidney transplant (KT), because subclinical acute reject

110 Many deceased-donor and living-donor kidney transplants (KTs) rely on commercial airlines for

111 isease or dying with little or no chances of kidney transplant (KTx) due to the high risk of relapse.

112 tive complications (UOC) affect up to 15% of kidney transplants (KTX).

113 DDKT) recipients (n = 1288) and living-donor kidney transplant (LDKT) recipients (n = 812).

114 ransplant (DDKT), 6.3% received living donor kidney transplant (LDKT), 22.6% died, 22.0% were removed

115 rtality, and living-donor and deceased-donor kidney transplants (LDKT/DDKT) March 15-April 30, 2020 t

116 mpared surveillance biopsies in living donor kidney transplants (LDKTx) from HLA matched siblings (te

117 ellitus type on the likelihood of SPK versus kidney transplant listing pre- and post-PAS.

118 lso suggest that receiving a pancreas (after kidney) transplant may have a protective effect on the k

119 th sodium acetate modified alloimmunity in a kidney transplant model, generating tolerance dependent

120 of infection was also higher in children of kidney-transplanted mothers born preterm or with low bir

121 we analyzed n = 156069 deceased donor adult kidney transplants occurring from 2000 to 2016.

122 h similar baseline characteristics receive a kidney transplant on the same day: 1 from a standard cri

123 afe and effective for early active AMR after kidney transplant or abrupt increases in donor-specific

124 Whether donor leukocytes persist within kidney transplants or play any role in rejection is unkn

125 ut SES gradients may negatively impact other kidney transplant outcomes and could be used to identify

126 (BMI) is a known risk factor associated with kidney transplant outcomes and is incorporated for deter

127 Kidney transplant outcomes are limited by toxicities ass

128 Pediatric kidney transplant outcomes associated with expanded-crit

129 he effect of donor-recipient sex matching on kidney transplant outcomes have reported heterogenous an

130 he effect of donor-recipient sex matching on kidney transplant outcomes in the United Kingdom.

131 Until results from APOL1 Long-term Kidney Transplant Outcomes Network ancillary studies are

132 Kidney transplant outcomes of Indigenous Australians are

133 Kidney transplant outcomes of indigenous Australians are

134 The KDRI is widely used in kidney transplant outcomes research.

135 data for GDF15 for associations with patient kidney transplant outcomes.

136 The number of patients waiting to receive a kidney transplant outstrips the supply of donor organs.

137 ansplant, and the third had a pancreas after kidney transplant (PAK).

138 This report on kidney transplant pathology details clarifications and r

139 A kidney-transplanted patient, unvaccinated against yellow

140 We performed a retrospective study on 1029 kidney transplant patients (2004-2016) with the followin

141 Thus, transgender kidney transplant patients can present novel challenges

142 ells from T-cell-mediated RJ and nonrejected kidney transplant patients, cells from leukocyte Ig-like

143 ate with the use of checkpoint inhibitors in kidney transplant patients.

144 TCZ) for treatment of cAMR in HLA-sensitized kidney transplant patients.

145 urine excretion will correlate with IFTA in kidney transplant patients.

146 onal recovery dynamics were assessed for 599 kidney transplants performed at the Leiden Transplant Ce

147 Of 229,188 kidney transplants performed during the study period, 15

148 jected to ischemia-reperfusion injury during kidney transplant, phagocytes coexpressing the F4/80 and

149 Only 0.18% of the kidney transplant population died of SARS-CoV-2 infectio

150 Adult listings for SPK and kidney transplant (pre-PAS, January 2010 to October 29,

151 Patients who had engaged in the kidney transplant process received more intensive patter

152 after experiencing differing exposure to the kidney transplant process.

153 Kidney transplant program performance in the United Stat

154 lant recipients from the Columbia University kidney transplant program who required hospitalization f

155 COIIN recruited 2 separate cohorts of kidney transplant programs.

156 Patterns of TRR-based kidney transplant rates differ from waitlist-based rates

157 Patterns of population- and waitlist-based kidney transplant rates differed, most notably in the No

158 ta to compare waitlist- and population-based kidney transplant rates.

159 The first reported case of yellow fever in a kidney transplant recipient in Brazil and the re-emergen

160 r, whether these structural features predict kidney transplant recipient outcomes is unclear.

161 se report, we presented a 63-year-old female kidney transplant recipient who presented with dyspnea a

162 We are reporting the first case of CG in a kidney transplant recipient with kidney disease of unkno

163 b (anti-PD-1) for ~9 months to a 57-year-old kidney transplant recipient with metastatic cutaneous sq

164 rug-resistant Cytomegalovirus retinitis in a kidney transplant recipient.

165 this report, we present a dual-organ (heart/kidney) transplant recipient who was found to have COVID

166 intage with posttransplantation mortality in kidney transplant recipients (KTR).

167 gulation therapy is frequently prescribed to kidney transplant recipients (KTRs) for prevention and t

168 med HLA class II antibodies and donor HLA in kidney transplant recipients (KTRs) remain unestablished

169 atment of urinary tract infections (UTIs) in kidney transplant recipients (KTRs) with oral antibiotic

170 yvitamin D (1,25D) predict renal outcomes in kidney transplant recipients (KTRs), with conflicting re

171 o study the MDSC effects on the evolution of kidney transplant recipients (KTRs).

172 es are a common and burdensome problem among kidney transplant recipients (KTRs).

173 Among 9845 kidney transplant recipients across centers, 144 were ho

174 Our findings indicate that immunosuppressed kidney transplant recipients admitted to the hospital wi

175 Included patients were living-donor kidney transplant recipients aged 18 years and older.

176 2014-December 2018) comprising 4 transgender kidney transplant recipients and 2 transgender living do

177 ystis pneumonia has dramatic consequences in kidney transplant recipients and a targeted prophylaxis

178 (20%) occurred as urinary tract pathogens in kidney transplant recipients and as digestive tract path

179 Low 25(OH)D is common in kidney transplant recipients and associated with late CM

180 ibility of acute and cGVHD in pancreas after kidney transplant recipients and be able to recognize th

181 oregulation performance occurs frequently in kidney transplant recipients and is an independent predi

182 p sequencing on 510 fecal specimens from 168 kidney transplant recipients and metagenomic sequencing

183 We enrolled 45 kidney transplant recipients and performed virus serolog

184 Whether kidney transplant recipients are capable of mounting an

185 Although criteria for kidney transplant recipients are selective, patients wit

186 Kidney transplant recipients are thought to experience a

187 We identified hospitalized adult kidney transplant recipients at 12 transplant centers in

188 Kidney transplant recipients at high risk for infections

189 clinical and histologic phenotyping from 224 kidney transplant recipients between 2011 and 2017.

190 care coverage of immunosuppressant drugs for kidney transplant recipients ceases 36 months after tran

191 The study included 108 kidney transplant recipients converted from CNI to belat

192 The study included 108 kidney transplant recipients converted from CNI to belat

193 t Recipients to determine how many pediatric kidney transplant recipients developed delayed graft fun

194 hould not be used in high-immunological risk kidney transplant recipients due to a perceived increase

195 itored for the development of de novo DSA in kidney transplant recipients during the first-year postt

196 Two cohorts of kidney transplant recipients enrolled in the Deteriorati

197 We studied kidney transplant recipients experiencing rejection unde

198 013 multicenter Deceased Donor Study of 2430 kidney transplant recipients from 1298 donors, we assess

199 Sharing data, HCV-infected adult first-time kidney transplant recipients from 2014 to 2017 were exam

200 nts (SRTR) to study 141 661 Medicare-primary kidney transplant recipients from January 1, 1999 to Dec

201 We report 15 kidney transplant recipients from the Columbia Universit

202 linical histologic and functional changes in kidney transplant recipients from the prospective Genomi

203 evaluated 296 807 adult (age > 17) solitary kidney transplant recipients from the Scientific Registr

204 Kidney transplant recipients had excess stroke deaths, p

205 urin inhibitors (CNI) in HLA-sensitized (HS) kidney transplant recipients has not been established.

206 Authors of reports on trials in kidney transplant recipients have suggested that C1-INH

207 Kidney transplant recipients infected with COVID-19 shou

208 n of immunosuppression Medicare coverage for kidney transplant recipients led to lower costs of -$307

209 Kidney transplant recipients may be at a high risk of de

210 Kidney transplant recipients must take immunosuppressant

211 center study in pediatric (>=1 to <18 years) kidney transplant recipients randomized at 4 to 6 weeks

212 rt analysis suggests that in hypersensitized kidney transplant recipients receiving tacrolimus-based

213 RA) CD8(+) T cells-in blood samples from 284 kidney transplant recipients recruited 1 year post-trans

214 DWF and DC-GF in kidney transplant recipients represent differing clinica

215 Ten kidney transplant recipients tested positive for severe

216 ation-09 study in which we randomized stable kidney transplant recipients to Tac withdrawal or mainte

217 In view of the recent literature, kidney transplant recipients treated by belatacept immun

218 Sixty-nine kidney transplant recipients were randomized from 4 US t

219 A total of 2100 adult kidney transplant recipients were recruited from all 23

220 n immune-suppressed patients, in particular, kidney transplant recipients who can develop polyomaviru

221 Five-year mortality for kidney transplant recipients who developed an infection

222 risk (aHR: (1.84) 1.91(1.98) , P < .001) for kidney transplant recipients who developed an infection,

223 d a single-center prospective cohort of 1258 kidney transplant recipients who underwent a water-loadi

224 Among 1682 kidney transplant recipients who underwent an allograft

225 al study of a consecutive cohort of solitary kidney transplant recipients who were transplanted betwe

226 We report results on 95 first-time human kidney transplant recipients with 1-year follow-up.

227 etry along with serum antibody testing in 18 kidney transplant recipients with active coronavirus dis

228 uctions in immunosuppressive therapy for all kidney transplant recipients with active COVID-19 may no

229 Kidney transplant recipients with C-/SC-TCMR have height

230 In sum, hospitalized kidney transplant recipients with COVID-19 have higher r

231 Kidney transplant recipients with COVID-19 have presenta

232 The trial included 20 kidney transplant recipients with donor-specific, antibo

233 We conducted a retrospective review of kidney transplant recipients with metastatic cancer who

234 Six kidney transplant recipients with metastatic cancers tha

235 d controlled trial involving 130 nondiabetic kidney transplant recipients with stable function betwee

236 We report that IgG from kidney transplant recipients with TG, but not from those

237 We aimed to compare the stroke deaths in kidney transplant recipients with the general population

238 educed the rate of delayed graft function in kidney transplant recipients without adversely affecting

239 4%) as urinary pathogens in heart, lung, and kidney transplant recipients, and as digestive tract pat

240 erapy is achievable and safe in living-donor kidney transplant recipients, and is associated with few

241 hould not be used in high-immunological risk kidney transplant recipients, due to a perceived increas

242 t Tac can be safely withdrawn in a subset of kidney transplant recipients, immune mechanisms that und

243 Among 17 628 kidney transplant recipients, there were 158 stroke deat

244 cohort study was conducted across all single kidney transplant recipients, transplanted between 2011

245 G) reduces rates of acute rejection in adult kidney transplant recipients, yet little is known about

246 Comorbidity is increasingly common in kidney transplant recipients, yet the implications for t

247 eys with moderate to severe AKI in pediatric kidney transplant recipients.

248 nd identify risk factors for stroke death in kidney transplant recipients.

249 (T(FH)) cells and B cells during ABMR in 105 kidney transplant recipients.

250 s as well as reduction of CNIs for pediatric kidney transplant recipients.

251 r studies of secondary stroke prevention for kidney transplant recipients.

252 tion among heart, lung, liver, pancreas, and kidney transplant recipients.

253 transplant outcomes is highly variable among kidney transplant recipients.

254 ociated with high morbidity and mortality in kidney transplant recipients.

255 rom immunosuppression in a clinical trial of kidney transplant recipients.

256 on cardiac structure and function in stable kidney transplant recipients.

257 a major cause of morbidity and mortality in kidney transplant recipients.

258 ry and delayed graft function (DGF) in human kidney transplant recipients.

259 D] level is associated with CMV infection in kidney transplant recipients.

260 une function, and deficiency is common among kidney transplant recipients.

261 is is an uncommon opportunistic infection in kidney transplant recipients.

262 with immune-mediated kidney diseases and to kidney transplant recipients.

263 ug response prediction, cancer diagnosis, or kidney transplant rejection.

264 or the prediction and clinical management of kidney transplant rejection.

265 ine samples from patients experiencing acute kidney transplant rejection.

266 actors for COVID-19 disease in patients with kidney transplants remain poorly defined.

267 Experience in simultaneous liver-kidney transplant (SLK) using DCD donors, however, remai

268 y allocated for KAT or simultaneous pancreas-kidney transplant (SPK) (n = 7,378).

269 1.0-1.6) and a longer length of stay for the kidney transplant surgery (mean difference, 1.7 d; 95% C

270 useful therapeutic approach in recipients of kidney transplant to minimise the burden of general immu

271 gest that it would be ethical to offer a pig kidney transplant to selected patients who have a life e

272 We assessed outcomes of third and fourth kidney transplants, to aid decision making on the most s

273 We tested multiple regulatory CBMPs in kidney transplant trials to establish the safety of regu

274 A retrospective multicentric study (9 French kidney transplant units of the Spiesser group) included

275 Similarly, deceased donor kidney transplant volume dropped from 367 to 202 (-45%),

276 Racial disparity in kidney transplant wait-listing persisted even after adju

277 In the UK, 1 in 3 patients on the National Kidney Transplant Waiting List (NKTWL) are suspended fro

278 ted Kingdom, 1 in 3 patients on the National Kidney Transplant Waiting List (NKTWL) is suspended from

279 Alloimmune kinetics in patients on a kidney transplant waiting list do not appear to be relat

280 (HIV) and end-stage renal disease was on the kidney transplant waitlist awaiting an organ offer, incl

281 Although over 90 000 people are on the kidney transplant waitlist in the United States, some ki

282 Racial disparity in kidney transplant waitlisting persisted even after adjus

283 Despite these efforts, rates of kidney transplant waitlisting within the first year of e

284 Conversely, en bloc pediatric kidney transplant was more common in the US.

285 Seventeen kidney transplants were analyzed.

286 Kidney transplants were performed from BALB/c(H2(d)) to

287 ns to limit podocyte injury in patients with kidney transplants, which may lead to eventual glomerula

288 er and were less likely to have a preemptive kidney transplant, while the timing and proportions of d

289 Which kidney transplant will last longer?

290 phenotype to that seen after engraftment in kidney transplants with or without CI.

291 ng acute AMR in recipients of deceased-donor kidney transplants with preformed donor-specific antibod

292 associated with high recurrence rates after kidney transplant, with devastating outcomes.

293 Candidates received deceased donor kidney transplants within 3 years of wait listing more f

294 schemia (CI); (3) donor kidneys subjected to kidney transplant without CI (Txp); and (4) donor kidney

295 5% CI, 1.2-3.4) was increased in children of kidney-transplanted women compared with controls.

296 ney-transplanted women, all children born to kidney-transplanted women in Denmark from 1964 to 2016 w

297 ort- and long-term risks of children born to kidney-transplanted women remains limited.

298 A total of 124 children of kidney-transplanted women were identified and matched on

299 long-term risk of infections in offspring of kidney-transplanted women, all children born to kidney-t

300 infection were increased in children born to kidney-transplanted women.